Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Varespladib for Prevention of Acute Chest Syndrome in Sickle Cell Disease
NCT01522196Phase 2Terminated
- Sponsor
- Anthera Pharmaceuticals, Inc.
- Start
- Feb 2012
- Primary completion
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of varespladib in acute chest syndrome (ACS), sponsored by Anthera Pharmaceuticals, Inc.. Started Feb 2012; status: terminated.
02
Drugs
varespladib
03
Conditions
acute chest syndrome (ACS)
Beyond the preview
Go deeper on NCT01522196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01522196.